Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice. Issue 10 (3rd May 2021)

• Record Type: Journal Article
• Authors: Morimoto, Takeshi; Uchida, Kazutaka; Sakakibara, Fumihiro; Kinjo, Norito; Ueda, Shinichiro
• Is Part Of: Pharmacoepidemiology and drug safety. Volume 30:Issue 10(2021)
• Page Start: 1321
• Page End: 1331
• Publication Date: 2021-05-03
• Subjects: antiplatelets -- atrial fibrillation -- hemorrhage -- ischemic event -- oral anticoagulants -- registry; Pharmacoepidemiology -- Periodicals; Chemotherapy -- Periodicals; Epidemiology -- Periodicals; 615.705
• DOI: 10.1002/pds.5228
• Languages: English
• ISSNs: 1053-8569

Abstract

Abstract: Purpose: Antiplatelet therapy (APT) is challenging in patients taking oral anticoagulants (OACs) for nonvalvular atrial fibrillation (NVAF) with concomitant atherosclerotic diseases. We scrutinized the generalizability of recent randomized clinical trials showing OAC use alone was superior to OAC plus antiplatelet use in patients with NVAF and coronary artery diseases (CAD). Methods: We conducted a historical multicenter registry at 71 centers in Japan. The inclusion criterion was taking OACs for NVAF. The exclusion criteria were mechanical heart valves or history of pulmonary thrombosis or deep vein thrombosis. Consecutive patients (N = 7826) were registered in February 2013 and were followed until February 2017. The co‐primary endpoints were ischemic events and major bleedings. Secondary endpoints were ischemic stroke, hemorrhagic stroke, and all‐cause mortality. Results: The mean patient age was 73 years; 67% were men. Antiplatelets were administered in 25% of patients and 27% had history of CAD. Cumulative incidences of ischemic events and major bleedings at 4 years were 5.9% and 9.6% in the APT group and 5.3% and 7.0% in the No‐APT group, respectively. The adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) of the APT group for ischemic events and major bleedings were 1.12 (0.84–1.49) and 1.26 (1.01–1.57), respectively. The adjusted HRs (95% CIs) for ischemic stroke, hemorrhagic stroke, and all‐cause mortality were 1.16 (0.86–1.57), and 1.31 (0.70–2.48), and 1.02 (0.82–1.26), respectively. Conclusions: APT in patients taking OACs for NVAF did not prevent ischemic events but significantly increased major bleedings in the real‐world setting.